MedTrace Logo

Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus

NCT05867017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-01-07

No results posted yet for this study

Summary

Hospitalized patients with severe COVID-19 have an increased incidence of insulin resistance, impaired beta cell function, glucose intolerance (prediabetes), and overt type 2 diabetes (T2D) compared to non-hospitalized patients with COVID-19 and COVID-19 negative individuals on long-term follow up.

Conditions

Interventions

OTHER

Measure of physiologic parameters

Participants will have hepatic muscle and adipose tissue insulin sensitivity tested

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Ralph DeFronzo, MD · University of Texas Health Science Center San Antonio

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-10
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05867017 on ClinicalTrials.gov